作者:Xiaohui Du、Paul J. Dransfield、Daniel C.-H. Lin、Simon Wong、Yingcai Wang、Zhongyu Wang、Todd Kohn、Ming Yu、Sean P. Brown、Marc Vimolratana、Liusheng Zhu、An-Rong Li、Yongli Su、Xianyun Jiao、Jiwen (Jim) Liu、Gayathri Swaminath、Thanhvien Tran、Jian Luo、Run Zhuang、Jane Zhang、Qi Guo、Frank Li、Richard Connors、Julio C. Medina、Jonathan B. Houze
DOI:10.1021/ml4005123
日期:2014.4.10
We recently reported the discovery of a potent GPR40 full agonist AM-1638 (1). Herein, we describe our efforts in improving the drug-like properties of the full agonists through the systematic introduction of polar groups in the C-, D-, and A-rings. This led to the discovery of new GPR40 full agonists with significantly improved pharmacokinetic propeties. Compound 8 and 20 also showed potent in vivo efficacy in oral glucose tolerance tests in mice in addition to the improvement in properties.